Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE)

Circulation

Volumn 109, Issue 6, 2004, Pages 726-732

  Johnson, B Delia ^a   Kip, Kevin E ^a   Marroquin, Oscar C ^b   Ridker, Paul M ^c   Kelsey, Sheryl F ^a   Shaw, Leslee J ^d   Pepine, Carl J ^e   Sharaf, Barry ^f   Bairey Merz, C Noel ^g   Sopko, George ^h   Olson, Marian B ^a   Reis, Steven E ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Atlanta Cardiovasc Res Institute   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Amyloid; Coronary disease; Inflammation; Proteins; Women

Indexed keywords

C REACTIVE PROTEIN; SERUM AMYLOID A;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RISK FACTOR; STROKE;

ADULT; AGED; APOLIPOPROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTORS; SERUM AMYLOID A PROTEIN; SYNDROME;

EID: 10744226950     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000115516.54550.B1     Document Type: Article

References (56)

1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [published erratum appears in N Engl J Med 1999;340:1376]. N Engl J Med. 1999;340:448-454.
2. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [published erratum appears in N Engl J Med 1999;340:1376]. N Engl J Med. 1999;340:448-454.
3. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
4. Malle E, Steinmetz A, Raynes J. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis, 1993;102:131-146.
5. Pussinen PJ, Malle E, Metso J, et al. Acute-phase HDL in phospholipid transfer protein (PLTP)-mediated HDL conversion. Atherosclerosis. 2001;155:297-305.
6. Artl A, Marsche G, Lestavel S, et al. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 2000;20:763-772.
7. Banka CL, Yuan T, de Beer MC, et al. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995;36:1058-1065.
8. Ridker PM, Buring JE, Shih J. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
9. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis. 1999;10(suppl 1):S9-S12.
10. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
11. Fukuda Y, Hoshino S, Tanaka I, et al. Examination of serum amyloid a protein in kidney transplant patients. Transplantation Proc. 2000;32:1796-1798.
12. Cunnane G, Grehan S, Geoghegan S, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol. 2000;27:58-63.
13. Pezzilli R, Melzi d'Eril GM, Morselli-Labate A, et al. Serum amyloid A, procalcitonin, and C-reactive protein in early assessment of severity of acute pancreatitis. Dig Dis Sci. 2000;45:1072-1078.
14. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999;37:381-388.
15. Ebeling P, Teppo A, Koistinen H, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with type II diabetes. Diabetologia. 1999;42:1433-1438.
16. Hartmann A, Eide T, Fauchald P, et al. Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrol Dial Transplantation. 1997;12:161-167.
17. Mayer JM, Raraty M, Slavin J, et al. Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis. Br J Surg. 2002;89:163-171.
18. Malle E, de Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest. 1996;26:427-435.
19. Poole S, Walker D, Gaines Das RE, et al. The first international standard for serum amyloid A protein (SAA): evaluation in an international collaborative study. J Immunol Methods. 1998;214:1-10.
20. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
21. Alexander RW. Inflammation and coronary artery disease. N Engl J Med. 1994;331:468-469.
22. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436.
23. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095-4103.
24. Mattila KJ, Valtonen VV, Nieminen MS, et al. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis. 1998;26:719-734.
25. Gupta S. Chronic infection in the aetiology of atherosclerosis: focus on Chlamydia pneumoniae. Atherosclerosis. 1999;143:1-6.
26. Khovidhunkit W, Memon R, Feingold K, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181(suppl 3):S462-S472.
27. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol. 1999;84:1018-1022.
28. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537-547.
29. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
30. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
31. Sano TM, Tanaka AM, Namba MM, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation. 2003;108:282-285.
32. Rifai N, Joubran R, Yu H, et al. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem. 1999;45:1967-1973.
33. Yamada T, Miida T. Serum amyloid A remains at physiological concentrations in coronary atherosclerosis. Clin Chem. 1997;43:193. Letter.
34. Liuzzo G, Biasucci L, Gallimore J, et al. Prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
35. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
36. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 2000;35:358-362.
37. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079-2084.
38. Ridker P, Rifai N, Pfeffer M, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
39. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-466.
40. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
41. Erren M, Reinecke H, Junker R, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999;19:2355-2363.
42. Hoffmeister A, Rothenbacher D, Bazner U, et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol. 2001;87:262-266.
43. Bairey Merz C, Kelsey S, Pepine C, et al. The Women's Ischemia Syndrome (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol. 1999;33:1453-1461.
44. Sharaf B, Pepine C, Kerensky R, et al. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] study angiographic core laboratory. Am J Cardiol. 2001;87:937-941.
45. Gillmore J, Lovat L, Persey M, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-29.
46. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
47. Bevilacqua M, Pober J, Wheeler M, et al. Interleukin-1 acts on cultured human vascular endothelium to increase adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest. 1985;76:2003-2011.
48. Galea J, Armstrong J, Gadsdon P, et al. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16:1000-1006.
49. Libby P, Wyler D, Janicka M, et al. Differential effects of human interleukin-1 on growth of human fibroblasts and vascular smooth muscle cells. Arteriosclerosis. 1985;5:186-191.
50. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
51. Maseri A. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. N Engl J Med. 1997;336:1014-1016.
52. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
53. Brennan M, Penn M, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
54. Ridker P, Cushman M, Stampfer M, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
55. Danesh J, Muir J, Wong YK, et al. Risk factors for coronary heart disease and acute-phase proteins: a population-based study. Eur Heart J. 1999;20:954-959.
56. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity: a clue to serum amyloid A's principal function. Lab Invest. 1992;66:778-785.